The National Heart, Lung, and Blood Institute (NHLBI) awarded a $234,000 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to the University of Colorado-Denver to develop "hemostatic erythrocytes" - modified red blood cells targeted to collagen and fibrin clots. The goal is to create a novel hemorrhage control technology that can rapidly plug and stabilize non-compressible bleeding wounds, buying time for surgical interventions. The research will focus on synthesizing the targeted red blood cells, testing their ability to enhance clot formation and stability in vitro, and evaluating their circulation, clot binding, and hemostatic effects in an in vivo animal model. This work seeks to impact the management and survival of patients experiencing severe, non-compressible hemorrhage, which is a major cause of morbidity and mortality worldwide.
Generated 3/18/25, 3:03 AM